References
- Davison JM, Homuth V, Jevakala A, Conrad KP, Karmanchi SA, Quaggin S, et al. New aspects in the pathophysiology of preeclampsia. J Am Soc Nephrol. 2004;9:2440–8.
- Friedman SA, Schiff E, Emeis JJ, Dekker GA, Sibai BM. Biochemical corroboration of endothelial involvement in severe preeclampsia. Am J Obstet Gynecol. 1995;172:202–3.
- Lattuada A, Rossi E, Calzarossa C, Candolfi R, Mannucci PM. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS13) in pregnant women with HELLP microangiopathic syndrome. Haematologica. 2003;88:1029–34.
- Borchiellini A, Fijnvandraat K, Ten Cate JW, Pajkrt D, Van Deventer SJ, Pasterkamp G, et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-d-arginine vasopressin in humans. Blood. 1996;88:2951–8.
- Van Mourik JA, Boertjes R, Huisveld IA, Fijnvandraat K, Pajkrt D, van Genderen PJ, et al. von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell puerturbation. Blood. 1999;94:179–85.
- Ruggeri ZM. Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost. 2003;1:1335–42.
- Huizinga EG, Tsuji S, Romijn RA, Schiphorst ME, De Groot PG, Sixma JJ, et al. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science. 2002;297:1176–9.
- Arya M, Anvari B, Romo GM, Cruz MA, Dong JF, McIntire LV, et al. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib–IX complex: studies using optical tweezers. Blood. 2002;99:3971–7.
- Molvarec A, Rigo J, Boze T, Derzsy Z, Cervenak L, Mako V, et al. Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia. Thromb Haemost. 2009;101:305–11.
- Joubert K. Standards of the body mass and body length of birth in Hungary on the basis of the 1990–1996 nation-wide liveborn. Magy Noorv L. 2000;63:155–63.
- Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005;129:93–100.
- Analía S, Susana M, Carlos M, Roberto V, Patricia C, Adriana W, et al. Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium. Blood Coagul Fibrinolysis. 2003;14:647–51.
- Hulstein JJ, De Groot PG, Silence K, Veyradier A, Fijnheer R, Lenting PJ. A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood. 2005;106:3035–42.
- Stepanian A, Cohen-Moatti M, Sanglier T, Legendre P, Ameziane N, Tsatsaris V, et al. von Willebrand factor and ADAMTS13: a candidiate couple for preeclampsia pathophysilogy. Arterioscler Thromb Vasc Biol. 2011;31(7):1703–9.
- Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol. 1999;180:499–506.
- Nadar SK, Al YE, Blann AD, Lip GY. Thrombomodulin,von Willebrand factor and E selectin as plasma markers of endothelial damage dysfunction and activation in pregnancy induced hypertension. Thromb Res. 2004;113:123–8.
- Hulstein JJ, Heimel VR, Franx A, Lenting JP, Bruinse WH, Silence K, et al. Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome. J Thromb Haem. 2006;4:2569–75.